BACKGROUND: Glycogen storage disease type III (GSDIII) is a rare autosomal recessive disorder due to glycogen debranching enzyme (GDE) deficiency. It results in a multisystemic disease with predominant hepatic and myopathic symptoms. While frequent social maladjustment has been observed in our clinical practice, cognitive and psychological disturbances have never been assessed. The aim of this pilot study was to examine and characterize the cognitive profile of patients with GSDIII. METHODS: Seven patients (six women and one man, mean age: 38.7 ± 11.6 years) with GSDIII underwent a neuropsychological set of tests assessing global cognitive efficiency, executive functions, social cognition, apathy, and episodic memory. RESULTS: All patients presented previous psychopathological history. We observed attention fluctuations for each patient, and impaired global cognitive efficiency with deficiencies in executive functions in 5/7 patients. Emotional skills (social cognition) were impaired in five patients. Memory was mostly preserved. CONCLUSION: The impairment in social cognition (recognition of emotions and ability to attribute mental states to others) and executive functions observed could be a consequence of orbito-frontal dysfunction due to the abnormal glycogen metabolism characteristic of the underlying disease. These results are consistent with the hypothesis of a central nervous system involvement in patients with GSDIII, but need to be confirmed in future research. This could explain the social and economic difficulties, and the lack of compliance to the medical follow-up presented by these patients. It suggests that these disturbances need to be taken into account when planning the medical management of patients with GSDIII.
BACKGROUND:Glycogen storage disease type III (GSDIII) is a rare autosomal recessive disorder due to glycogendebranching enzyme (GDE) deficiency. It results in a multisystemic disease with predominant hepatic and myopathic symptoms. While frequent social maladjustment has been observed in our clinical practice, cognitive and psychological disturbances have never been assessed. The aim of this pilot study was to examine and characterize the cognitive profile of patients with GSDIII. METHODS: Seven patients (six women and one man, mean age: 38.7 ± 11.6 years) with GSDIII underwent a neuropsychological set of tests assessing global cognitive efficiency, executive functions, social cognition, apathy, and episodic memory. RESULTS: All patients presented previous psychopathological history. We observed attention fluctuations for each patient, and impaired global cognitive efficiency with deficiencies in executive functions in 5/7 patients. Emotional skills (social cognition) were impaired in five patients. Memory was mostly preserved. CONCLUSION: The impairment in social cognition (recognition of emotions and ability to attribute mental states to others) and executive functions observed could be a consequence of orbito-frontal dysfunction due to the abnormal glycogen metabolism characteristic of the underlying disease. These results are consistent with the hypothesis of a central nervous system involvement in patients with GSDIII, but need to be confirmed in future research. This could explain the social and economic difficulties, and the lack of compliance to the medical follow-up presented by these patients. It suggests that these disturbances need to be taken into account when planning the medical management of patients with GSDIII.
Authors: B J Ebbink; F K Aarsen; C M van Gelder; J M P van den Hout; N Weisglas-Kuperus; J Jaeken; M H Lequin; W F M Arts; A T van der Ploeg Journal: Neurology Date: 2012-04-25 Impact factor: 9.910
Authors: Aurélie Funkiewiez; Maxime Bertoux; Leonardo Cruz de Souza; Richard Lévy; Bruno Dubois Journal: Neuropsychology Date: 2011-09-05 Impact factor: 3.295
Authors: Fanny Mochel; Raphael Schiffmann; Marjan E Steenweg; Hasan O Akman; Mary Wallace; Frédéric Sedel; Pascal Laforêt; Richard Levy; J Michael Powers; Sophie Demeret; Thierry Maisonobe; Roseline Froissart; Bruno Barcelos Da Nobrega; Brent L Fogel; Marvin R Natowicz; Catherine Lubetzki; Alexandra Durr; Alexis Brice; Hanna Rosenmann; Varda Barash; Or Kakhlon; J Moshe Gomori; Marjo S van der Knaap; Alexander Lossos Journal: Ann Neurol Date: 2012-09 Impact factor: 10.422
Authors: G M Talente; R A Coleman; C Alter; L Baker; B I Brown; R A Cannon; Y T Chen; J F Crigler; P Ferreira; J C Haworth; G E Herman; R M Issenman; J P Keating; R Linde; T F Roe; B Senior; J I Wolfsdorf Journal: Ann Intern Med Date: 1994-02-01 Impact factor: 25.391
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Priya S Kishnani; Stephanie L Austin; Pamela Arn; Deeksha S Bali; Anne Boney; Laura E Case; Wendy K Chung; Dev M Desai; Areeg El-Gharbawy; Ronald Haller; G Peter A Smit; Alastair D Smith; Lisa D Hobson-Webb; Stephanie Burns Wechsler; David A Weinstein; Michael S Watson Journal: Genet Med Date: 2010-07 Impact factor: 8.822
Authors: Emanuele Monda; Marta Rubino; Michele Lioncino; Francesco Di Fraia; Roberta Pacileo; Federica Verrillo; Annapaola Cirillo; Martina Caiazza; Adelaide Fusco; Augusto Esposito; Fabio Fimiani; Giuseppe Palmiero; Giuseppe Pacileo; Paolo Calabrò; Maria Giovanna Russo; Giuseppe Limongelli Journal: Front Pediatr Date: 2021-02-25 Impact factor: 3.569
Authors: Ghada Hijazi; Anna Paschall; Sarah P Young; Brian Smith; Laura E Case; Tracy Boggs; Sathya Amarasekara; Stephanie L Austin; Surekha Pendyal; Areeg El-Gharbawy; Kristen L Deak; Andrew J Muir; Priya S Kishnani Journal: Mol Genet Metab Rep Date: 2021-11-11
Authors: Annieke Venema; Fabian Peeks; Marlies de Bruijn-van der Veen; Foekje de Boer; Marieke J Fokkert-Wilts; Charlotte M A Lubout; Bibi Huskens; Eric Dumont; Sandra Mulkens; Terry G J Derks Journal: JIMD Rep Date: 2021-10-10